U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07329946) titled 'Immuno-inflammatory Response of Erdosteine in COPD' on Dec. 10, 2025.
Brief Summary: Chronic obstructive pulmonary disease (COPD) remains a major contributor to global morbidity and mortality, exposing healthcare systems to a significant economical and social load. Indeed, acute severe COPD exacerbations are the events that contribute most to the overall disease burden. Current management strategies are aimed at maximizing symptom-free periods, reduce hospitalizations, improve exercise tolerance, overall health status, and quality of life. Key pathophysiological mechanisms involved in COPD exacerbations (defined as acute worsening o...